Navigation Links
Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
Date:3/7/2008

SAN DIEGO, March 7 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced that it will release financial results for the three and twelve months ended December 31, 2007 after market close on Thursday, March 13, 2008.

Jonathan Lim, MD, President and Chief Executive Officer, Gregory Frost, PhD, Vice President and Chief Scientific Officer, Robert Little, Vice President and Chief Commercial Officer, and David Ramsay, Vice President and Chief Financial Officer, will host an investment community conference call beginning at 8:00 a.m. PT (11:00 a.m. ET) on Friday, March 14, 2008, to provide a pipeline update.

Individuals interested in participating in the conference call may do so by dialing 888-256-9044 for domestic callers or 706-643-5585 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the Company's web site at http://www.halozyme.com. A replay will be available on Halozyme's web site for 30 days. A telephone replay will be available for 48 hours by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers, and entering reservation code 38622372.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Halozyme Contact

David A. Ramsay

Chief Financial Officer

(858) 704-8260

dramsay@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
2. Halozyme Therapeutics Amends Stockholder Rights Plan
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
5. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
6. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
7. ExonHit Therapeutics - 2007 Financial Results
8. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
9. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
10. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
11. CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics today announced that ... after the company changed focus to making analytical tools for biopharmaceutical quality control. ... technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and David Erickson ...
(Date:4/19/2017)... ... April 19, 2017 , ... WHO: Peggy Lillis ... through education and advocacy. Founded in 2010 in memory of a single-parent mom ... foundation has become the most-consulted source for patient-focused information on C. diff infections ...
(Date:4/19/2017)... Calif. , April 19, 2017  As ... Drug Abuse and Heroin Summit ,  Proove® Biosciences, ... study analyzing genetics, environmental, and lifestyle factors to ... from the University of Southern California (USC), the ... , and Proove publish results showing that Proove ...
(Date:4/19/2017)... Mass. , April 19, 2017   ... results from the multi-center Procalcitonin MOnitoring SEpsis (MOSES) ... print issue of Critical Care Medicine . ... Mortality in Severe Sepsis Patients: Results From the ... use of the B·R·A·H·M·S PCT (procalcitonin) assay to ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):